Anti-kappa and anti-lambda detect surface light chain immunoglobulins on normal and neoplastic B-cells in human lymphoid tissue. In normal lymphoid tissue the kappa and lambda cell ratio is approximately 2:1, but values in excess of that ratio indicate monoclonality caused by either a lymphoproliferative disorder or neoplasia such as lymphoma.
The double stain antibody provided by Biocare’s MACH 2 Double Stain Detection Kit (DAB and Fast Red) allows the investigator to simultaneously see both kappa (M) (brown) and lambda (P) (red) on the same tissue section, thus allowing the end-user a more accurate and easier assessment of both stains. Image analysis of a digitally scanned slide provides rapid highly accurate kappa and lambda cell counts. The resulting whole slide section determination of a kappa/lambda ratio enables easier diagnosis of disease.
It needs to be noted that the kappa/lambda ratio in the image analyzed is 4.25 which substantially exceeds the normal ratio of 2:0. Analysis of a whole section provides more statistically meaningful results than just an analysis of a single image, or a random manual count by a pathologist.
Share this Post:
Flagship Biosciences Inc.
Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.
With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:
Make informed pipeline decisions that will accelerate the right clinical path
Enable critical go/no go decisions based on confirmation of action
Design, implement and evaluate prototype diagnostic strategies
Differentiate commercial strategies to increase probability of success
Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship's technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.